MDXG(MiMedx Group, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $242.02M | $267.84M | $321.48M | $348.88M | $418.63M |
| 毛利润 | $202.39M | $219.53M | $266.84M | $288.81M | $345.62M |
| 营业利润 | −$7.05M | −$14.73M | $37.12M | $58.87M | $63.89M |
| 净利润 | −$10.29M | −$30.20M | $58.23M | $42.42M | $48.58M |
| 经营现金流 | −$1.98M | −$17.89M | $26.77M | $66.20M | $74.00M |
| 自由现金流 | −$5.20M | −$19.41M | $24.79M | — | — |
| 摊薄每股收益 | $-0.15 | $-0.33 | $0.37 | $0.28 | $0.32 |